Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06337383
Other study ID # 12.2021 ANGELMAN
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date March 15, 2022
Est. completion date June 2024

Study information

Verified date April 2024
Source IRCCS Eugenio Medea
Contact Martina Baggio
Phone +39 340 802 1282
Email martina.baggio@lanostrafamiglia.it
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The goal of this observational cross-sectional study is to establish the prevalence of autism spectrum disorder in children and adolescents with Angelman syndrome. The main questions it aims to answer are: - which clinical variables differentiate AS patients with and without Autism Spectrum Disorder between genetics, epilepsy, pharmacotherapy, behavioural problems, parenting style and parents' perceived stress. - which clinical variables differentiate parenting styles and levels of perceived stress. Data from neuropsychological, speech therapy and physiotherapeutic assessments are collected during regular clinical follow-ups, regarding: cognitive development ("Bayely Scales of Infant Development-III", Cognitive Scale) and adaptive behaviour; Autism and Autism Spectrum Disorder ("Autism Diagnostic Observational Schedule-2"); parental stress and parenting styles; social-communicative skills; motor development.


Recruitment information / eligibility

Status Recruiting
Enrollment 46
Est. completion date June 2024
Est. primary completion date June 2024
Accepts healthy volunteers No
Gender All
Age group 4 Years to 14 Years
Eligibility Inclusion Criteria: - genetically confirmed diagnosis of Angelman Syndrome - chronological age between 4-15 years Exclusion Criteria: - genetic examination pending report - mental age lower than 12 months - brain injury acquired in the peri- or postnatal period

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Italy I.R.C.C.S. "E.Medea" Conegliano Treviso

Sponsors (1)

Lead Sponsor Collaborator
IRCCS Eugenio Medea

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Total score of the Autism Diagnostic Observation Schedule -2 (ADOS-2), Module 1, The ADOS-2 consists of different semi-structured standard situations that induce communication, social interaction and imaginative play and that is considered a gold standard in autism assessment; Module 1, that does not require the use of speech, is employed.
In particular, our outcome of interest is the "Total score", given by the sum of the "Communication and Reciprocal Social Interactions" and the "Stereotyped Behaviors and Restricted Interests" raw scores. Higher scores correspond to a greater presence of autistic features (min:0; max:28; cut-off for autism spectrum disorder:11; cut-off for autism disorder:16).
Once at recruitment
Secondary Age-equivalent score at the Cognitive Scale of the Bayley Scales of Infant Development - 3rd version (Bayley-III) The Bayley-III Cognitive Scale is used to assess cognitive level. In particular, age-equivalent scores are considered (min: 1 months; max: 42 months). Once at recruitment
Secondary Total Stress score at the Parent Stress Index - 4th edition (PSI-4) questionnaire PSI-4 is a standardised parent self-report instrument to explore perceived stress in their role and therefore to identify situations at risk of dysfunctional parent-child system. It is composed of two subscales: the child domain, that identifies six child characteristics, and the parent domain, that describes seven stressors related to parent and family characteristics. Our outcome of interest is the Total Stress score, given by the sum of the scores obtained at the "Child domain" and the "Parent domain".
Higher scores correspond to a greater level of parental stress.
Once at recruitment
Secondary Global score at the Aberrant Behaviour Checklist (ABC) The ABC is a questionnaire that measures psychiatric symptoms and behavioural disturbance in individuals with severe or very severe intellectual disability across 5 domains: irritability, agitation and crying; lethargy/social withdrawal; stereotypic behaviour; hyperactivity/noncompliance; inappropriate speech. It is useful to assess the possible effects of medications or other treatments. In particular is considered the Global score, obtained from the sum of the scores at each subscale (min: 0; max: 171; higher scores correspond to a greater level of behavioural problems). Once at recruitment
Secondary Total Raw score at the Social Communication Questionnaire - Current version(SCQ) Children's communication, social and interpersonal skills are indirectly investigated through the Social Communication Questionnaire- Current version. It screens for characteristics associated with Autism (cut-off: 22) and Autism Spectrum Disorder (cut-off: 15) such as social interaction, communication and repetitive behaviour, considering the last three months (min: 0; max: 33). Once at recruitment
See also
  Status Clinical Trial Phase
Recruiting NCT05293184 - The Global Angelman Syndrome Registry
Completed NCT00004351 - Study of Phenotype and Genotype Correlations in Patients With Contiguous Gene Deletion Syndromes N/A
Enrolling by invitation NCT06139172 - Promoting Prosocial Behavior in Syndromic Intellectual and Developmental Disabilities N/A
Enrolling by invitation NCT03655223 - Early Check: Expanded Screening in Newborns
Recruiting NCT06229769 - Natural History Study for Patients With Angelman Syndrome
Enrolling by invitation NCT03836300 - Parent and Infant Inter(X)Action Intervention (PIXI) N/A
Completed NCT03235037 - Clinical Trial of Levodopa/Carbidopa ( Sinemet) Therapy in Angel Man Syndrome N/A
Recruiting NCT05100810 - Angelman Syndrome Natural History Study-FAST UK
Completed NCT03644693 - Nutritional Formulation for Angelman Syndrome N/A
Completed NCT03358823 - Study on the Brain Network of Angelman Syndrome
Recruiting NCT05945576 - IDMet (RaDiCo Cohort) (RaDiCo-IDMet)
Completed NCT02670694 - Sleep Abnormalities in Rare Genetic Disorders: AS, RTT, and PW N/A
Recruiting NCT04768803 - Ghrelin in Patients With a Rare Disease Associated With Intellectual Disability, and Hyperphagia, and/or Overweight, and/or Obesity
Recruiting NCT05630066 - Study to Investigate the Pharmacokinetics and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype. Phase 2
Completed NCT00348933 - Dietary Supplements for the Treatment of Angelman Syndrome N/A
Recruiting NCT05011851 - An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Angelman Syndrome Phase 2
Terminated NCT03882918 - An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individuals With Angelman Syndrome Phase 3
Completed NCT02996305 - A Study in Adults and Adolescents With Angelman Syndrome (STARS) Phase 2
Completed NCT02056665 - Study to Evaluate the Efficacy and Safety of Minocycline in Angelman Syndrome Phase 2
Completed NCT01281475 - A Trial of Levodopa in Angelman Syndrome Phase 2/Phase 3